渤健公司:阿尔茨海默病早期疗法Leqembi皮下制剂在华获优先审评资格

美股速递
Feb 09

渤健公司宣布,其用于治疗早期阿尔茨海默病的Leqembi皮下制剂生物制品许可申请,已获得中国国家药品监督管理局的优先审评资格。这一认定将有望加速该创新疗法在中国的审批进程,为患者提供更便捷的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10